Přejít k obsahu
Merck

Přeskočit na

C3742

Chk2 Inhibitor II hydrate

≥98% (HPLC)

Synonyma:

2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate

Přihlásit pro zobrazení organizačních a smluvních cen.

Vybrat velikost

Změnit zobrazení
Velikost baleníSkladová položkaDostupnostCena
5 mg
Obraťte se na zákaznický servis a vyžádejte si informaci o dostupnosti.
5 490,00 Kč
4 666,50 Kč

O této položce

Empirický vzorec (Hillův zápis):
C20H14ClN3O2 · xH2O
Číslo CAS:
Molekulová hmotnost:
363.80 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:

4 666,50 Kč

Ceníková cena5 490,00 KčUložit 15 %

Obraťte se na zákaznický servis a vyžádejte si informaci o dostupnosti.

Požádejte o hromadnou objednávku
Technický servis
Potřebujete pomoc? Náš tým zkušených odborníků je vám k dispozici.
Dovolte nám, abychom vám pomohli


Quality Level

assay

≥98% (HPLC)

form

solid

color

off-white to tan

solubility

DMSO: ≥2 mg/mL (warmed)

originator

Johnson & Johnson

storage temp.

2-8°C

SMILES string

O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N

InChI

1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)

InChI key

UXGJAOIJSROTTN-UHFFFAOYSA-N

Gene Information

human ... CHEK2(11200)

Biochem/physiol Actions

Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer.
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC50 = 15 nM; Ki = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC50 = 3 μM and 7.6 μM, respectively).

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Porovnat podobné položky

Zobrazit úplné porovnání

Zobrazit rozdíly

1 of 1

Tato položka
S7076220486G5793
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

>98% (HPLC)

form

solid

form

solid

form

solid

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥2 mg/mL (warmed)

solubility

DMSO: ≥12 mg/mL

solubility

DMSO: 5 mg/mL

solubility

DMSO: 10 mg/mL, clear

originator

Johnson & Johnson

originator

GlaxoSmithKline

originator

-

originator

GlaxoSmithKline


Skladovací třída

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Nevidíte správnou verzi?

Potřebujete-li konkrétní verzi, můžete vyhledat daný certifikát podle čísla dávky nebo čísla šarže.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů



Lauren E Williamson et al.
Journal of virology, 93(8) (2019-02-08)
The human B cell response to natural filovirus infections early after recovery is poorly understood. Previous serologic studies suggest that some Ebola virus survivors exhibit delayed antibody responses with low magnitude and quality. Here, we sought to study the population
Elena Oropeza et al.
Science advances, 9(26), eadf2860-eadf2860 (2023-06-30)
Cell cycle dysregulation is prerequisite for cancer formation. However, it is unknown whether the mode of dysregulation affects disease characteristics. Here, we conduct comprehensive analyses of cell cycle checkpoint dysregulation using patient data and experimental investigations. We find that ATM
Ran Guo et al.
Antioxidants (Basel, Switzerland), 11(6) (2022-06-25)
Reactive oxygen species (ROS) act as a signaling intermediate to promote cellular adaptation to maintain homeostasis by regulating autophagy during pathophysiological stress. However, the mechanism by which ROS promotes autophagy is still largely unknown. Here, we show that the ATM/CHK2/ULK1



Globální číslo obchodní položky

Skladová položkaGTIN
C3742-25MG04061832445267
C3742-5MG04061832445274

Questions

Reviews

No rating value

Active Filters